This effect is not unique to Ozempic and may happen with any significant or fast reduction in body weight, regardless of the method used
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
00:04:18 Vickie Danaher So if you read the studies, you may notice that the approved dosages and dosage forms of orforglipron are different than what was used in the clinical trials
Zhong, F., Chen, Y., Chen, J., Liao, H., Li, Y., & Ma, Y
We dont think of bad air as a gut issue, but it is
The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination